Skip to main content
micro-community-banner
 
  • Saved

made a Post

Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer - PubMed

1 Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 2 Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34409252/

  • Saved

made a Post

Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced cancer - PubMed

doi: 10.1002/onco.13945. Online ahead of print. 1 Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, MA, 02114. 2 Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34409698/

  • Saved

made a Post

Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy - PubMed

doi: 10.1080/07357907.2021.1970761. Online ahead of print. 1 Department of Oncology, Queen Alexandra University Hospital, Portsmouth Hospitals NHS Trust, United Kingdom. 2 Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34409906/

  • Saved

made a Post

Precision therapy for RET-altered cancers with RET inhibitors - PubMed

Rearranged during transfection (RET) is involved in the physiological development of some organ systems. Activating RET alterations via either gene fusions or point mutations are potent oncogenic drivers in non-small ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34391699/

  • Saved

Commented on 's Post

SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer - PubMed

Resistance is the major cause of treatment failure and disease progression in non-small cell lung cancer (NSCLC). There is evidence that hypoxia is a key microenvironmental stress associated with resistance ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34381712/

Show More Comments

  • 1 month 1 week
    Key Points • Conclusion/Relevance: “We speculate that SIRT1/PGC-1α/PPAR-γ signaling may represent a molecular metabolic mechanism underlying hypoxia-induced chemoresistance in the NSCLC microenvironment, and targeting hypoxia-related metabolic adaptation may be a potential Show More
  • Saved

Commented on 's Post

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

Domenico Galetta, Academic Editor Keywords: EGFR-genes, drug therapy, lung cancer, metastasis, survival analysis, TKI In 2020, lung cancer was still the leading cancer worldwide in terms of mortality. NSCLC accounts ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345514/

Show More Comments

  • 1 month 1 week
    Key Points • Conclusion/Relevance: “The aim of our retrospective, longitudinal and analytic study was to analyze the survival of EGFR-mutated patients treated beyond the second line of treatment. We confirmed in Show More
  • Saved

Commented on 's Post

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI? - PubMed

Lung cancer is the leading cause of cancer-related death globally and poses a considerable threat to public health. Asia has the highest prevalence of epidermal growth factor receptor (EGFR) mutations ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34374490/

Show More Comments

  • 1 month 1 week
    Key Points • Conclusion/Relevance: “This review focuses on these key issues, and provides a flow diagram with proposed treatment options for metastatic EGFRm NSCLC, aiming to provide guidance for clinical practice.” • The use Show More
  • Saved

made a Post

Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1α pathway

Demethyleneberberine (DMB) is a natural active component of medicinal plant Cortex phellodendri chinensis with favorable bioactivity. However, the role of DMB in suppressing non-small cell lung cancer (NSCLC) remains unknown. ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S094471132100221X?via=ihub

  • Saved

made a Post

Identification of predictors for brain metastasis in newly diagnosed non-small cell lung cancer: a single-center cohort study - European Radiology

Objectives To identify clinical and staging chest CT characteristics predictive of brain metastasis in patients with newly diagnosed NSCLC dichotomized according to resectability. Methods Patients newly diagnosed with NSCLC of ..... see more

Source : https://link.springer.com/article/10.1007/s00330-021-08215-y

  • Saved

made a Post

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer - PubMed

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver mutations. Although the best studied are common alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34353680/

  • Saved

made a Post

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era - PubMed

1 Oncology Department, CHU Amiens, Université de Picardie Jules Vernes, 80000 Amiens, France. 2 Oncology Department, Professeur Zafisaona Gabriel Hospital, Université de Mahajanga, Mahajanga 401, Madagascar. 3 Faculté de Médecine, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34359788/

  • Saved

made a Post

Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC) - PubMed

Two different schemes of novel substituted quinoline derivatives were designed and synthesized via simple reaction steps and conditions. A comparative molecular docking study was carried out on two different types ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34364055/

  • Saved

made a Post

Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC) - PubMed

Two different schemes of novel substituted quinoline derivatives were designed and synthesized via simple reaction steps and conditions. A comparative molecular docking study was carried out on two different types ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34364055/

  • Saved

made a Post

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs - PubMed

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34359849/

  • Saved

made a Post

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer - PubMed

doi: 10.1158/1078-0432.CCR-21-0273. Online ahead of print. 1 Department of Medical Oncology, Kindai University [email protected] 2 Department of Medical Oncology, Catalan Institute of Oncology. 3 Medicine, Hematology/Oncology, David Geffen School of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34301751/

  • Saved

made a Post

Retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients - PubMed

Mutations of EGFR, KRAS and TP53 should be routinely detected in clinical practice to better guide the immunotherapy for NSCLC patients. Future investigations are warranted to illustrate the potential mechanisms ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34325991/

  • Saved

made a Post

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer - PubMed

RELAY confirmed the clinical relevance of combining EGFR and VEGF(R)-targeting therapies, previously investigated in smaller phase 2-3 trials of erlotinib and bevacizumab. However, the meaningful PFS benefit observed in the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34281470/

  • Saved

made a Post

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases - PubMed

doi: 10.1007/s10637-021-01147-w. Online ahead of print. 1 Department of Clinical Oncology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. [email protected] 2 Department of Respiratory Medicine, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34215931/

  • Saved

made a Post

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer - PubMed

doi: 10.1158/1078-0432.CCR-21-0273. Online ahead of print. 1 Department of Medical Oncology, Kindai University [email protected] 2 Department of Medical Oncology, Catalan Institute of Oncology. 3 Medicine, Hematology/Oncology, David Geffen School of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34301751/

  • Saved

Lilly

Sponsored

Do you consider your patients’ exon status when choosing treatment?

Tailor your 1st-line treatment for your patients with EGFR mut+ mNSCLC who have exon 21 (L858R) substitution.

Learn More


EGFR=epidermal growth factor receptor; mNSCLC=metastatic non-small cell lung cancer; mut+=mutation-positive.
PP-RB-US-3530 03/2021 © Lilly USA, LLC 2021. All rights reserved.